
Solid Biosciences (SLDB) Stock Forecast & Price Target
Solid Biosciences (SLDB) Analyst Ratings
Bulls say
Solid Biosciences is a life sciences company that is developing a portfolio of gene therapy candidates for neuromuscular and cardiac diseases. They are currently focused on five programs, including SGT-003 for the treatment of Duchenne muscular dystrophy, which is showing promising early results in clinical trials. With a differentiated approach to gene therapy and upcoming clinical milestones, we believe Solid Biosciences has the potential to become a top player in the field of genetic medicine and generate significant revenue in the future.
Bears say
Solid Biosciences is currently facing financial struggles, reporting no revenue in 1Q26 and projecting a net loss of $1.72 per share for 2026. While they have a strong cash balance of $381M, this may not be enough to sustain their operations until 1H28 due to ongoing research and development efforts. Additionally, the company's gene therapy treatments for Duchenne muscular dystrophy and other diseases may face significant challenges in the regulatory process, potentially delaying potential market entry and hindering the company's financial performance.
This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Solid Biosciences (SLDB) Analyst Forecast & Price Prediction
Start investing in Solid Biosciences (SLDB)
Order type
Buy in
Order amount
Est. shares
0 shares